1. Generated operational cash of 218 cr vs 181 cr in Q1 22
2. Free cash flow of 124 cr vs 98 cr in Q1 23
3. Completed the buy back with total cash outflow of 310 cr including taxes and other expenses
2. Free cash flow of 124 cr vs 98 cr in Q1 23
3. Completed the buy back with total cash outflow of 310 cr including taxes and other expenses
4. Raw material costs coming down but coal prices increased in current qtr
5. Supply of PAP and DCDA is stable and improving
6. Work on the DCDA project is going on smoothly and expecting results in less than 2 years.
5. Supply of PAP and DCDA is stable and improving
6. Work on the DCDA project is going on smoothly and expecting results in less than 2 years.
7. R&D spend in Q2 23 was 25 cr vs 45 cr in Q2 22. Expected R&D spend at 40-45 cr in each qtr going forward
8. Net debt at 553 cr as compared to 613 cr. Paid some long term debt
8. Net debt at 553 cr as compared to 613 cr. Paid some long term debt
9. Paracetamol gross margins are lower compared to other products
10. Paracetamol Revenues : 529 cr of revenues in Q2 23 vs in 293 cr Q2 22.
10. Paracetamol Revenues : 529 cr of revenues in Q2 23 vs in 293 cr Q2 22.
There is no one off in paracetamol sales, increase in sales is due to raw material (PAP) prices were high in last year and availability was not enough (One of the chinese manufacturer was shifting to another location, No producer in India)
11. Granules have some marquee customers in USA and granules is trying to convert them from Paracetamol API to formulation
12. Launch of Paracetamol formulation is happening in Q3 23
13. Capacity Utilization of Paracetamol is 90 to 95%
12. Launch of Paracetamol formulation is happening in Q3 23
13. Capacity Utilization of Paracetamol is 90 to 95%
14. EBITDA margins long term target is to reach to 25% right now its 21.1% in Q2 23
15. In Q1 23 reefer container price was $12000 to $13000 while in Q3 23 its $8000 to $8500 and expected to go down further. Pre-covid it was around $4000-$5000
15. In Q1 23 reefer container price was $12000 to $13000 while in Q3 23 its $8000 to $8500 and expected to go down further. Pre-covid it was around $4000-$5000
16. There is no pent up demand on paracetamol, customers were waiting for raw material situation to stabilize. There is a shift from competitor to granules for paracetamol
17. Granules imports DCDA and PAP from china. There was shortage of PAP in china but situation is normal now and indian manufacturers also started manufacturing PAP and other international manufacturers came up.
DCDA they had supplier from Europe but now energy costs has gone up thatβs why granules is procuring it from china
18. Not buying PAP from sadhana nitro chem but buying from other companies. There was a issue with quality from one of the supplier but now itβs stabilized. No one is making Nitro Benzene route PAP and selling in market
19. Investing in Oncology and biologics 300 cr each
19. Investing in Oncology and biologics 300 cr each
β’ β’ β’
Missing some Tweet in this thread? You can try to
force a refresh
γ
